Obesity
← 실적 발표
01
02
03
04 05 06
톤
AI
자본지출
A1 A2 A3
PFE
FY2025 Q4
개선
Pfizer, Inc. 실적 발표
Buzzberg 분석
Monthly GLP-1 3944 could be competitive and best-in-class among mono agonists
Pfizer reported a strong 2025 with solid operational growth excluding COVID, driven by new product launches and cost discipline. The key focus on the call was the positive preliminary data for its monthly-dosed obesity drug candidate (danuglipron/3944), which validates its differentiation strategy. Management reaffirmed 2026 guidance reflecting LOE headwinds and continued investment. 2025 full-year revenue was $62.6B (down 2% operational), with 6% operational growth excluding COVID products.
Buzzberg 분석 Monthly GLP-1 3944 could be competitive and best-in-class among mono agonists Pfizer reported a strong 2025 with solid operational growth excluding COVID, driven by new product launches and cost discipline. The key focus on the call was the positive preliminary data for its monthly-dosed obesity drug candidate (danuglipron/3944), which validates its differentiation strategy. Management reaffirmed 2026 guidance reflecting LOE headwinds and continued investment. 2025 full-year revenue was $62.6B (down 2% operational), with 6% operational growth excluding COVID products. 전체 분석 보기분석 접기
Pfizer reported a strong 2025 with solid operational growth excluding COVID, driven by new product launches and cost discipline. The key focus on the call was the positive preliminary data for its monthly-dosed obesity drug candidate (danuglipron/3944), which validates its differentiation strategy. Management reaffirmed 2026 guidance reflecting LOE headwinds and continued investment. 2025 full-year revenue was $62.6B (down 2% operational), with 6% operational growth excluding COVID products.
- Pipeline prioritization led to a $4.4B non-cash impairment, including deprioritizing disitamab vedotin in bladder cancer.
- Positive Phase 2b VESPR-3 data for obesity drug 3944 showed ~10-12.3% placebo-adjusted weight loss with monthly dosing, supporting plans for Phase 3.
- Management reaffirmed FY2026 revenue guidance of $59.5-62.5B and EPS of $2.80-3.00.
매출$17.557B보고값
주당순이익(EPS)$0.66보고값
매출총이익률69.97%보고값
영업이익률21.01%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Obesity/Pipeline
Pfizer targets first obesity portfolio approvals in 2028
AI
Pfizer expanding AI compute capacity to over 1,200 GPUs
핵심 내용 3개 더 보기
Guidance
Management reaffirms FY2026 guidance
Capital allocation
Pfizer prioritizes maintaining and growing dividend
Growth strategy
Company expects end-of-decade growth from pipeline, BD, and launches
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $17.557B | 보고값 |
| 주당순이익(EPS) | $0.66 | 보고값 |
| 매출총이익률 | 69.97% | 보고값 |
| 영업이익률 | 21.01% | 보고값 |
| 잉여현금흐름 | $4.504B | 보고값 |
| 자본지출 | $0.845B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $2.80–$3.00 | $2.90 | 유지 |
| 매출 | FY2026 | $59.5B–$62.5B | $61B | 유지 |
AI, 자본지출 및 수요 분석
경영진 분석
Upbeat
Management repeatedly characterized 2025 as a very good year, emphasized over-delivery on commitments, and expressed confidence in the pipeline and 2026 catalysts.
경영진의 AI 분석
Management is aggressively scaling AI across R&D, manufacturing, and commercial, framing it as a key productivity lever. It plans to expand to more than 1,200 GPUs over the next two years and says AI is already improving launch execution, marketing ROI, and cost savings.
투자 및 생산능력
AI-related infrastructure investment is directionally increasing — management plans to expand to more than 1,200 GPUs, largely for R&D. Manufacturing optimization is also ongoing, with additional savings targeted in 2026 and 2027, though no total capex figure was provided.
아래에 언급된 기업 6개 모두 표시
기업발표 이후 수익률
파트너
파트너
Dave Denton
Pfizer's COVID product partnership with BioNTech continues to be a significant driver of reported financials, with a 50-50 profit split on Comirnaty, though the revenue decline for COVID products is factored into guidance.
근거
“as well as continued strong cost management. Future improvements in our manufacturing footprint remain a top priority going forward. As a reminder, over the past two years, our adjusted gross margins have generally remained in the mid to”
파트너
Dave Denton
The planned divestment of Pfizer's stake in ViiV Healthcare (a GSK-partnered HIV JV) provides significant capital for business development.
근거
“Additionally, the planned sale of our stake in VEV will further improve our balance sheet. When including the VEV proceeds, we have approximately $7 billion in BD capacity.”
투자 대상
투자 대상
Dr. Chris Boshoff
Seagen integration is successful, providing a robust pipeline (ADCs like PADSEV) and maintaining talent, positioning Pfizer for oncology growth.
근거
“We have a vibrant community of scientists and clinicians in Seattle. I believe we're one of the biggest employers in the biotech or biopharma industry in that region. Most of the colleagues actually remained at Pfizer, which is a testament”
공급망
공급망
Dave Denton
Pfizer's pipeline prioritization has led to a ~$4.4B non-cash impairment, including deprioritizing disitamab vedotin in bladder cancer due to competition from its own PADSEV, indicating a strategic resource shift within oncology. — Shows a direct market access trade-off between Roche's Padcev and its own pipeline, potentially reducing future competitive pressure from a different mechanism of action.
근거
“It is important to note that one of the asset indications we deprioritized was disidimab vedotin in bladder cancer is largely the result of the recently strong study readouts expanded indications, and related higher long-term revenue”
공급망
Dr. Chris Boshoff
Acknowledges that the VESPR-3 trial design had no down-titration allowed, an unusual feature for obesity trials, suggesting the trial may have understated the drug's true tolerability/effectiveness profile. — Indicates the trial results may be conservative; allowing down-titration in Phase III could improve tolerability and thereby commercial success, competing directly with Lilly and Novo's products.
근거
“Just to remember for this study, there was no step-down titration was allowed, which is unusual for obesity trials. But that will obviously not happen in the phase three study. We will allow down titration.”
외부 신호
공급망 알파 · 3발표 이후 수익률
Pfizer's pipeline prioritization has led to a ~$4.4B non-cash impairment, including deprioritizing disitamab vedotin in bladder cancer due to competition from its own PADSEV, indicating a strategic resource shift within oncology.
근거
“It is important to note that one of the asset indications we deprioritized was disidimab vedotin in bladder cancer is largely the result of the recently strong study readouts expanded indications, and related higher long-term revenue proje…”
The obesity market is cited as being largely out-of-pocket (OOP) with high willingness to pay (~$250-350/month), which may alter standard reimbursement expectations and speed market access.
근거
“First is the out-of-pocket category... we see that there are high willingness to pay out-of-pocket across all mature markets... and we see the price point being across 250 to 350.”
Acknowledges that the VESPR-3 trial design had no down-titration allowed, an unusual feature for obesity trials, suggesting the trial may have understated the drug's true tolerability/effectiveness profile.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 6개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.